Smart Patients Get Smart Care™
The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients
While the incidence of Richter’s transformation has not changed dramatically with the introduction of targeted therapies, those who received CLL / SLL treatment in the targeted therapy era appear to have a lower risk of Richter’s transformation.
Pirtobrutinib is a useful treatment option to temporarily manage Richter’s transformation, but long-term treatments are still needed.
Chimeric antigen receptor T-cell (CAR-T) therapy can provide durable remissions in a subset of patients with Richter’s transformation.
This was a very complex basic science presentation from iwCLL 2023 by Erin Parry, MD. Ph.D. of Dana Farber Cancer Institute in Boston, MA on the evolution of CLL (chronic lymphocytic leukemia) to Richter’s transformation (RT),
Fixed-duration glofitamab, a bispecific T-cell engager (BITE) monoclonal antibody, induces durable complete remissions (CR) and has a manageable safety profile in patients with Richter’s transformation.
Atezolizumab, obinutuzumab, and venetoclax combination therapy is active in patients with untreated DLBCL-Richter’s Syndrome (RS).
This new research identifies some of the genetic changes that drive the evolution of CLL to Richter’s syndrome.
Early results from a phase 1b/2 trial show that epcoritamab has a manageable safety profile and an encouraging response rate in patients with Richter syndrome.
Duvelisib plus venetoclax is a time-limited, all-oral regimen active in relapsed/refractory chronic lymphocytic leukemia (CLL) and Richter syndrome.
One click to our most popular content.
